Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma

被引:0
|
作者
Tsuji, Yuki [1 ]
Namisaki, Tadashi [1 ]
Takaya, Hiroaki [1 ]
Nishimura, Naoki
Noguchi, Ryuichi [1 ]
Asada, Shohei [1 ]
Shibamoto, Akihiko [1 ]
Kubo, Takahiro [1 ]
Iwai, Satoshi [1 ]
Tomooka, Fumimasa [1 ]
Koizumi, Aritoshi [1 ]
Matsuda, Takuya [1 ]
Tanaka, Misako [1 ]
Yorioka, Nobuyuki [1 ]
Inoue, Takashi [2 ]
Fujinaga, Yukihisa [1 ]
Nishimura, Norihisa [1 ]
Kitagawa, Koh [1 ]
Sato, Shinya [1 ]
Kaji, Kosuke [1 ]
Asada, Kiyoshi [3 ]
Mitoro, Akira [1 ]
Yoshiji, Hitoshi [1 ]
机构
[1] Nara Med Univ, Dept Gastroenterol, 840 Shijo Cho, Kashihara, Nara, Japan
[2] Nara Med Univ, Dept Evidence Based Med, 840 Shijo Cho, Kashihara, Nara, Japan
[3] Nara Med Univ, Clin Res Ctr, 840 Shijo Cho, Kashihara, Nara, Japan
关键词
AFP-L3; NLR; Radiofrequency ablation; Heterotopic recurrence; ALPHA-FETOPROTEIN; LYMPHOCYTE RATIO; BIOMARKERS; NEUTROPHIL; SURVIVAL; PLATELET;
D O I
10.1007/s10620-025-08884-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AimThe incidence of intrahepatic distant recurrence (IDR) of hepatocellular carcinoma (HCC) still remains high after radiofrequency ablation (RFA). However, serum alpha-fetoprotein (AFP) has insufficient screening power. This study aimed to identify risk factors for IDR in patients with post-RFA HCC. MethodA total of 112 patients with early-stage HCC who underwent RFA were divided into the IDR (n = 51) and non-IDR groups (n = 61). Serum samples were analyzed within 2 months after RFA. ResultsThe mean follow-up duration was 30.1 months. The recurrence-free survival rates at 1, 3, and 5 years were 20.8%, 42.4%, and 54.2%, respectively. The 1- and 5-year overall survival rates were 97.3% and 87.3%, respectively. Univariate and multivariate analyses revealed that the neutrophil-to-lymphocyte ratio [NLR, hazard ratio (HR) 2.40; 95% confidence interval (CI) 1.44-3.99] and lens culinaris agglutinin a-reactive fraction of alpha-fetoprotein (AFP-L3, (HR 1.02; 95% CI 1.01-1.04) were independently associated with post-RFA IDR. The cumulative recurrence rates at 5 years in the high NLR (>= 2.24) and high AFP-L3 (>= 0.2 ng/mL) groups were significantly higher than those in the low NLR (< 2.24) and low AFP-L3 (< 0.2 ng/mL) groups, respectively. The predictive accuracies of NLR, AFP-L3, and a composite index based on AFP-L3, and NLR for IDR were 66.2% (37.3% sensitivity, 95.1% specificity), 64.3% (47.1% sensitivity, 80.3% specificity), and 75.6% (68.6% sensitivity, 75.4% specificity), respectively. ConclusionThe combined model had significantly better prediction performance than either NLR or AFP-L3 alone. The NLR combined with an absolute AFP-L3 level is an effective marker for IDR in patients with post-RFA HCC.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma
    Huang, Jingjun
    Huang, Wensou
    Guo, Yongjian
    Cai, Mingyue
    Zhou, Jingwen
    Lin, Liteng
    Zhu, Kangshun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma
    Kang, Tae Wook
    Lim, Hyo Keun
    Cha, Dong Ik
    CLINICAL AND MOLECULAR HEPATOLOGY, 2017, 23 (01) : 95 - 101
  • [33] PREDICTION MODEL AND NOMOGRAM OF EARLY RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER RADIOFREQUENCY ABLATION BASED ON LOGISTIC REGRESSION ANALYSIS
    Ni, Zihao
    Wu, Bolin
    LI, Meng
    Han, Xue
    Hao, Xiaowen
    Zhang, Yue
    Cheng, Wen
    Guo, Cunli
    ULTRASOUND IN MEDICINE AND BIOLOGY, 2022, 48 (09) : 1733 - 1744
  • [34] Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma: Treatment Choice and Outcome
    Xie, Xiaoyan
    Jiang, Chunlin
    Peng, Zhengwei
    Liu, Baoxian
    Hu, Wenjie
    Wang, Ye
    Lin, Manxia
    Lu, Mingde
    Kuang, Ming
    JOURNAL OF GASTROINTESTINAL SURGERY, 2015, 19 (08) : 1466 - 1475
  • [35] Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation
    Seo, Ji Yeon
    Kim, Won
    Kwon, Jee Hye
    Jin, Eun Hyo
    Yu, Su Jong
    Kim, Hwi Young
    Jung, Yong Jin
    Kim, Donghee
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Lee, Hyo-Suk
    LIVER INTERNATIONAL, 2013, 33 (06) : 884 - 893
  • [36] A case of rapid intrahepatic dissemination of hepatocellular carcinoma after radiofrequency thermal ablation
    Nicoli, N
    Casaril, A
    Abu Hilal, M
    Mangiante, G
    Marchiori, L
    Ciola, M
    Invernizzi, L
    Campagnaro, T
    Mansueto, G
    AMERICAN JOURNAL OF SURGERY, 2004, 188 (02) : 165 - 167
  • [37] Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
    Canale, Matteo
    Ulivi, Paola
    Foschi, Francesco Giuseppe
    Scarpi, Emanuela
    De Matteis, Serena
    Donati, Gabriele
    Ercolani, Giorgio
    Scartozzi, Mario
    Faloppi, Luca
    Passardi, Alessandro
    Tamburini, Emiliano
    Valgiusti, Martina
    Marisi, Giorgia
    Frassineti, Giovanni Luca
    Gardini, Andrea Casadei
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 129 : 44 - 53
  • [38] The current role of radiofrequency ablation in the treatment of intrahepatic recurrent hepatocellular carcinoma
    Fu, Rong
    Ling, Wenwu
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (08) : 1340 - 1346
  • [39] Radiofrequency ablation versus surgical resection for intrahepatic hepatocellular carcinoma recurrence: a meta-analysis
    Chen, Xuxiao
    Chen, Yongjun
    Li, Qinyu
    Ma, Di
    Shen, Baiyong
    Peng, Chenghong
    JOURNAL OF SURGICAL RESEARCH, 2015, 195 (01) : 166 - 174
  • [40] Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome
    Zytoon, Ashraf Anas
    Ishii, Hiroshi
    Murakami, Koji
    El-Kholy, Mohamed Ramdan
    Furuse, Junji
    El-Dorry, Ahmed
    El-Malah, Adel
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2007, 37 (09) : 658 - 672